CytomX Therapeutics (6C1) Ownership - Who Owns CytomX Therapeutics?
CytomX Therapeutics (6C1) Ownership Overview
- 0.96% Insiders
- 20.65% Mutual Funds
- 1.21% Other Institutional Investors
- 13.15% ETFs
- 64.03% Public Companies and Individual Investors
The ownership structure of CytomX Therapeutics (DE:6C1) stock is a mix of institutional, retail, and individual investors. Approximately 35.01% of the company’s stock is owned by Institutional Investors, 0.96% is owned by Insiders, and 64.03% is owned by Public Companies and Individual Investors.
The ownership structure of CytomX Therapeutics (DE:6C1) stock is a mix of institutional, retail, and individual investors. Approximately 35.01% of the company’s stock is owned by Institutional Investors, 0.96% is owned by Insiders, and 64.03% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Jun 16, 2026 | Christopher Ogden | $4,953 | |
| Mar 18, 2026 | Yu-waye Chu | $136,611 | |
| Mar 18, 2026 | Sean A. Mccarthy | $763,781 | |
| Mar 18, 2026 | Christopher Ogden | $124,054 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Joseph Edelman | 10,439,185 | Institution | 4.79% | 23,415,092 |
| Vanguard | 10,353,910 | Institution | 4.75% | 23,223,820 |
| Ishares | 10,186,213 | Institution | 4.67% | 22,847,676 |
| Fidelity Select Portfolios | 8,782,240 | Institution | 4.03% | 19,698,564 |
| Vanguard Index Funds | 8,327,012 | Institution | 3.82% | 18,677,488 |
| Fidelity Securities Fund | 7,694,815 | Institution | 3.53% | 17,259,470 |
| Spdr | 5,936,690 | Institution | 2.72% | 13,315,996 |
| Fidelity Advisor Series Vii | 4,990,551 | Institution | 2.29% | 11,193,806 |
| Felix Baker | 4,975,826 | Institution | 2.28% | 11,160,778 |
| Fidelity Rutland Square Trust Ii | 3,746,123 | Institution | 1.72% | 8,402,554 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Fidelity Select Portfolios | 8,782,240 | Institution | 4.03% | 19,698,564 |
| Vanguard Index Funds | 8,327,012 | Institution | 3.82% | 18,677,488 |
| Fidelity Securities Fund | 7,694,815 | Institution | 3.53% | 17,259,470 |
| Fidelity Advisor Series Vii | 4,990,551 | Institution | 2.29% | 11,193,806 |
| Fidelity Rutland Square Trust Ii | 3,746,123 | Institution | 1.72% | 8,402,554 |
| Fidelity Concord Street Trust | 2,709,200 | Institution | 1.24% | 6,076,736 |
| Fidelity Capital Trust | 2,450,510 | Institution | 1.12% | 5,496,494 |
| Fidelity Salem Street Trust | 2,179,571 | Institution | 1.00% | 4,888,778 |
| Vanguard Scottsdale Funds | 1,215,158 | Institution | 0.56% | 2,725,599 |
| Schwab Capital Trust | 560,384 | Institution | 0.26% | 1,256,941 |
FAQ
Who Owns CytomX Therapeutics (DE:6C1)?
According to the latest TipRanks data, approximately 35.01% of the company's stock is held by institutional investors, 0.96% is held by insiders, and 64.03% is held by public companies and individual investors.
What percentage of CytomX Therapeutics (DE:6C1) stock is held by institutional investors?
According to the latest TipRanks data, approximately 35.01% of CytomX Therapeutics (DE:6C1) stock is held by institutional investors: 20.65% by mutual funds, 13.15% by ETFs and 1.21% by other institutional investors.
What percentage of CytomX Therapeutics (DE:6C1) stock is held by retail investors?
According to the latest TipRanks data, approximately 64.03% of CytomX Therapeutics (DE:6C1) stock is held by public companies and individual investors.
Who owns the most shares of CytomX Therapeutics (DE:6C1)?
Joseph Edelman owns the most shares of CytomX Therapeutics (DE:6C1).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.